KLAS Contact
Contact KLAS
Contact KLAS
2026 BEST IN KLAS
Preferences
Related Series
2023
2022
Digital Pathology 2026
Early Adoption & Technology Performance in an Emerging US Market
Author
Eder Lagemann
Author
Jonathan Christensen
Author
Spencer Corbett
The development and use of digital pathology software is rapidly growing in the US, thanks in large part to FDA clearance for several new vendors as well as continued progress toward digital pathology–specific reimbursement. Still, compared to global counterparts, adoption among US organizations remains early—it is estimated that fewer than 15% of US healthcare organizations have selected a digital pathology vendor and are at various stages of deployment and adoption. As the market evolves, organizations are evaluating—often for the first time—a growing range of digital pathology technologies, including image management systems (IMS), scanners, and AI tools. KLAS’ US Digital Pathology 2023 report focused on early outcomes and best practices; to aid organizations soon making purchase decisions, this year’s report goes further by offering a first-ever look into how these technologies meet customer needs across the digital pathology ecosystem. This analysis is anchored in customer feedback on IMS solutions being used for primary diagnosis, with respondents also sharing insights on the scanners and AI tools being considered or used alongside their IMS.
If you don't have a login, getting started is easy.
Writer
Carlisa Cramer
Designer
Breanne Hunter
Project Manager
Andrew Wright
This material is copyrighted. Any organization gaining unauthorized access to this report will be liable to compensate KLAS for the full retail price. Please see the KLAS DATA USE POLICY for information regarding use of this report. © 2026 KLAS Research, LLC. All Rights Reserved. NOTE: Performance scores may change significantly when including newly interviewed provider organizations, especially when added to a smaller sample size like in emerging markets with a small number of live clients. The findings presented are not meant to be conclusive data for an entire client base.